Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS

View Full Press Release
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte Conference